Sector
PharmaceuticalsOpen
₹375Prev. Close
₹365.15Turnover(Lac.)
₹27,512.85Day's High
₹380Day's Low
₹368.0552 Week's High
₹395.852 Week's Low
₹236.15Book Value
₹90.92Face Value
₹5Mkt Cap (₹ Cr.)
45,136.56P/E
0EPS
0.35Divi. Yield
0.14YESINTEK targets specific proteins that trigger inflammation, which presents new therapeutic options in the chronic management of autoimmune diseases.
Ethiopia, with a prevalence of 2-3%, is one of the top four nations in Sub-Saharan Africa for adult diabetics.
The combined cGMP inspection and pre-licensing inspection (PLI), which took place between July 15 and July 26, 2024, is the subject of this update.
Here are some of the stocks that may see significant price movement today: Tata Motors, Asian Paints, Divi’s Laboratories, etc.
The company's operating revenue climbed 3.7% to Rs 3,590.4 crore from Rs 3,462 crore in Q2 of FY24.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 600.3 | 600.3 | 600.3 | 600 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 10,312 | 10,315.7 | 7,492.6 | 7,307.1 |
Net Worth | 10,912.3 | 10,916 | 8,092.9 | 7,907.1 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 1,738.2 | 2,028.4 | 1,988.4 | 2,419.2 |
yoy growth (%) | -14.3 | 2.01 | -17.8 | -6.51 |
Raw materials | -808.2 | -798.3 | -827.7 | -1,049.4 |
As % of sales | 46.49 | 39.35 | 41.62 | 43.37 |
Employee costs | -367.7 | -390.2 | -344.8 | -408.6 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 139.7 | 358.8 | 388.5 | 305.8 |
Depreciation | -108.2 | -103.5 | -98 | -136.1 |
Tax paid | -53.6 | -78.3 | -111.9 | -67.3 |
Working capital | 268.3 | 64.09 | 379.5 | -311.6 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -14.3 | 2.01 | -17.8 | -6.51 |
Op profit growth | -80.44 | 9.26 | -10.11 | -46.23 |
EBIT growth | -60.99 | -7.82 | 27.02 | -43.18 |
Net profit growth | -69.3 | -36.38 | 84.86 | -54.07 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 14,195.8 | 11,174.2 | 8,184 | 7,143.1 | 6,300.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 14,195.8 | 11,174.2 | 8,184 | 7,143.1 | 6,300.5 |
Other Operating Income | 559.9 | 0 | 0 | 0 | 0 |
Other Income | 865.5 | 375.9 | 212.7 | 267.1 | 228.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,780.9 | 155.06 | 4,27,477.51 | 863.29 | 0.76 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,172.7 | 89.18 | 1,63,821.99 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,533.9 | 29.27 | 1,23,920.06 | 1,178.16 | 0.85 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,324.2 | 68.82 | 1,12,592.36 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,561.2 | 51.21 | 1,02,659.66 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairperson
Kiran Mazumdar Shaw
Non Executive Director
Ravi Mazumdar
Lead Independent Director
M Damodaran
Independent Director
Bobby Parikh
Company Sec. & Compli. Officer
Mayank Verma
Managing Director & CEO
SIDDHARTH MITTAL
Non Executive Director
Eric Vivek Mazumdar
Independent Director
Naina Lal Kidwai
Independent Director
Atul Dhawan
Independent Director
Rekha Mehrotra Menon
Independent Director
NICHOLAS ROBERT HAGGAR
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Biocon Ltd
Summary
Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. The Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in the year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw. Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind. In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International. Also in the same year, the company had received US funding for proprietary technologies. After a year, in 1990, Biocon had scaled up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level. Biocons R&D and manufacturing facilities received ISO 9001 certification from RWTUV, Germany during the period of 1993. In the year 1994, the company had established the Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector. The commercial success of Biocons proprietary fermentation plant leads to a 3-fold expansion during the year 1996 and also in the same year, the company had leveraged its technology platform to enter biopharmaceuticals and statins. Biocon had spearheads initiatives in human healthcare in the year 1997 through a dedicated manufacturing facilit
Read More
The Biocon Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹375.95 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Biocon Ltd is ₹45136.56 Cr. as of 02 Dec ‘24
The PE and PB ratios of Biocon Ltd is 0 and 4.02 as of 02 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Biocon Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Biocon Ltd is ₹236.15 and ₹395.8 as of 02 Dec ‘24
Biocon Ltd's CAGR for 5 Years at 5.33%, 3 Years at 0.07%, 1 Year at 54.23%, 6 Month at 12.84%, 3 Month at 2.73% and 1 Month at 11.67%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice